Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DZS
|
|||
| Former ID |
DNC002376
|
|||
| Drug Name |
1,3-bis(1,3-benzothiazol-2-ylthio)acetone
|
|||
| Synonyms |
1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propan-2-one; MLS000533100; AC1LOHTK; 1,3-bis(1,3-benzothiazol-2-ylthio)acetone; CBMicro_026328; CHEMBL1526448; MolPort-002-158-967; HMS2496A11; ZINC1029672; 1,3-dibenzothiazol-2-ylthioacetone; STK733322; AKOS001750462; MCULE-2850305009; ST006263; SMR000140538; BIM-0026345.P001; 1,3-bis(benzo[d]thiazol-2-ylthio)propan-2-one; SR-01000535355; SR-01000535355-1; 1,3-bis(1,3-benzothiazol-2-ylsulfanyl)propane-2-one; F1563-0006; A2660/0113409
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Glioma [ICD-11: 2A00.0] | Investigative | [1] | |
| Melanoma [ICD-11: 2C30] | Investigative | [1] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H12N2OS4
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)N=C(S2)SCC(=O)CSC3=NC4=CC=CC=C4S3
|
|||
| InChI |
1S/C17H12N2OS4/c20-11(9-21-16-18-12-5-1-3-7-14(12)23-16)10-22-17-19-13-6-2-4-8-15(13)24-17/h1-8H,9-10H2
|
|||
| InChIKey |
BWTBZOLHOSVREZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | AP endonuclease 1 (APEX1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Base excision repair | |||
| Pathway Interaction Database | HIF-2-alpha transcription factor network | |||
| WikiPathways | Spinal Cord Injury | |||
| TSH signaling pathway | ||||
| Base Excision Repair | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br J Cancer. 2011 Feb 15;104(4):653-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.